Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

This “rare” autism-linked genetic disorder may be far more common than scientists thought | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-09-25

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

This “rare” autism-linked genetic disorder may be far more common than scientists thought | ScienceDaily

sciencedaily.com · 2026-09-25

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mostly not supported

Every claim we could check holds up. Two of seven claims match the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

  • 2 supported
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredA genetic disorder strongly linked to autism may be dramatically more common than scientists thought, with thousands of cases potentially still undiagnosed.View evidenceHide evidence

As statedthousands of cases potentially still undiagnosed

Why this verdict

The abstract-level profile supports that the adjusted PMS prevalence estimate is substantially higher than prior estimates. However, the headline-prominence claim also says thousands of cases may remain undiagnosed; the supplied abstract profile does not quantify undiagnosed cases or directly establish that implication. The headline therefore goes beyond what can be verified at this evidence depth.

1

Study evidence

Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.

“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
Claim 2 of 7Not coveredThe analysis examined data from nearly 180,000 people with autism who had undergone genetic testing and combined information from ten sources including GeneDx, Labcorp, Ambry Genetics, SPARK, the Autism Sequencing Consortium, and several children's hospitals.View evidenceHide evidence

As statednearly 180,000 people

Why this verdict

The abstract profile supports use of data from 10 participating sources and 179,837 autism-tested cases. It does not identify the named sources such as GeneDx, Labcorp, Ambry Genetics, SPARK, or specific children's hospitals, so that portion cannot be verified from the supplied abstract-level evidence.

1

Study evidence

Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.

“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
2

Study evidence

Observed frequency of PMS diagnoses among individuals with autism across contributing sources ranged from 1% to ~2.5%.1%–2.5%

“The frequency of PMS diagnoses ranged from 1% to ~2.5%.”
Claim 3 of 7Not coveredThe article says the estimate implies more than 45,000 people in the United States could be living with Phelan-McDermid syndrome.View evidenceHide evidence

As statedmore than 45,000 people in the United States

Why this verdict

The prevalence estimate could be used to infer a U.S. case count, but the supplied abstract profile does not report a U.S.-specific estimate or a figure of more than 45,000 people. This implication is not verifiable from the provided paper profile.

1

Study evidence

Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.

“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
Claim 4 of 7Not coveredThe story argues that broader access to genetic testing could help identify people who currently have no diagnosis, and that several clinical trials are now underway for precision-medicine approaches to the disorder.View evidenceHide evidence

As statedbroader access to genetic testing; several clinical trials

Why this verdict

The profile supports that the study used genetic-testing cohorts and modeled PMS prevalence, but it does not evaluate broader genetic-testing access as an intervention, quantify diagnostic yield from expanded access, or mention ongoing precision-medicine clinical trials. The causal/policy and clinical-trial claims are therefore not verifiable at abstract depth.

1

Study evidence

Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.

“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
Claim 5 of 7Not coveredThe article highlights a recommendation that every child with autism undergo genetic testing, framed as important for targeted clinical trials and potential future treatments.View evidenceHide evidence

As statedevery child with autism

Why this verdict

The supplied abstract profile does not include a recommendation that every child with autism undergo genetic testing, nor does it discuss targeted clinical trials or future treatments. The claim may come from commentary or full-text discussion, but it is not verifiable from the abstract-level paper evidence supplied.

Claim 6 of 7SupportedResearchers led by scientists at Mount Sinai suggest that Phelan-McDermid syndrome may affect roughly 1 in 7,300 people.View evidenceHide evidence

As statedroughly 1 in 7,300 people

Why this verdict

The paper profile reports an adjusted general-population prevalence estimate of 13.7 per 100,000, equivalent to roughly 1 in 7,300 individuals. The Mount Sinai leadership detail is not independently evidenced in the supplied profile, but the scientific estimate as framed is supported.

1

Study evidence

Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.

“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
Claim 7 of 7SupportedAfter accounting for undiagnosed cases, limits in genetic testing, and people with Phelan-McDermid syndrome who do not meet autism criteria, the researchers estimated a prevalence of 13.7 cases per 100,000 people, or about 1 in 7,300.View evidenceHide evidence

As stated13.7 cases per 100,000 people; about 1 in 7,300

Why this verdict

The profile reports that the estimate incorporated extrapolations/adjustments for PMS cases without autism, autism diagnosis age limitations, variant type, assay sensitivity/coverage, and CDC autism-rate scaling, yielding 13.7 per 100,000, about 1 in 7,300. The story's wording about undiagnosed cases is a broad rendering of ascertainment/coverage adjustments, but the central prevalence estimate and adjustment-based framing are supported.

1

Study evidence

Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.

“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Uncertainty interval: the paper profile reports a 95% CI of 10.02–18.60 per 100,000 around the prevalence estimate.

    The story presentation includes the point estimate but does not mention the confidence interval, which is material because the result is a modeled prevalence estimate with uncertainty.

    From multisource prevalence modeling (secondary data aggregation with extrapolation/weighting)

  • Supporting descriptive finding: raw PMS diagnosis frequencies among autism-tested cohorts ranged from 1% to about 2.5%, but those raw results should not be directly compared because assays differed.

    The story presentation does not report the 1%–2.5% raw frequency range or the caution about direct comparison of raw source-level frequencies.

    From cross-source descriptive summarization

  • Limitation: the abstract-profile evidence does not itself establish U.S.-specific undiagnosed case counts, testing-access effects, or clinical-trial/treatment claims.

    The story includes U.S. case-count, undiagnosed-case, genetic-testing access, and clinical-trial implications, but these are not documented in the supplied abstract-level paper profile and therefore are interpretation-changing additions at this depth.

    From multisource prevalence modeling (secondary data aggregation with extrapolation/weighting)

5 things the story did carry across
  • Core design: multisource prevalence modeling using site-provided PMS diagnosis counts among autism-tested individuals from 10 participating sources totaling 179,837 autism cases.
  • Primary result: adjusted estimated general-population PMS prevalence of 13.7 per 100,000, approximately 1 in 7,300.
  • Model dependence: the estimate relies on multiple extrapolations and external inputs, including PMS without autism, autism diagnosis age limits, variant-type coverage, assay sensitivity/coverage, and CDC autism prevalence scaling.
  • Assay and ascertainment heterogeneity: contributing sources used different assays with different sensitivity/coverage, so raw frequencies are not directly comparable.
  • Context: prior PMS prevalence estimates were much lower, reported at 2.5–10 per million births, motivating the conclusion that PMS may be more common than previously estimated.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the population prevalence of Phelan–McDermid syndrome (PMS) by integrating diagnosis frequencies from multiple autism-tested cohorts across diverse sources and extrapolating to the general population with sensitivity/coverage adjustments.multisource prevalence modeling (secondary data aggregation with extrapolation/weighting)Expand

In plain English

Multisource prevalence modeling: aggregated counts of Phelan–McDermid syndrome (PMS) diagnoses among individuals tested for autism across 10 participating sources (n=179,837 autism cases), applied sensitivity and coverage adjustments and CDC autism-rate scaling to estimate general-population PMS prevalence.

Key findings

  • Aggregated data from 10 sources covering 179,837 autism-tested individuals were used as the basis for prevalence estimation.
  • Raw frequencies of PMS diagnoses among autism-tested cohorts ranged from 1% to ~2.5% across sources.1% to ~2.5%
“The study team reached out to a multitude of sources, including clinical genetic testing laboratories, research centers, and clinical centers.”
What this piece can’t prove
  • Contributing sources used assays with differing sensitivity/coverage; raw counts required adjustment and between-source heterogeneity may influence results.

1 further detail could not be confirmed from the summary.

2secondary dataCharacterize heterogeneity across contributing sources (e.g., observed PMS diagnostic frequency ranges and assay-dependent sensitivity differences) to motivate adjustment/weighting and interpretability of pooled estimates.cross-source descriptive summarizationExpand

In plain English

Across ten contributing sources (total n = 179,837 autism cases), the authors report observed frequencies of Phelan–McDermid syndrome (PMS) among tested individuals with autism that ranged from 1% to ~2.5%. The paper explicitly notes that contributing studies used assays with differing detection sensitivity, and therefore raw between-source frequency estimates are not directly comparable. The reported between-source heterogeneity and assay-dependent sensitivity differences were used to motivate adjustments/weighting in the subsequent pooled prevalence estimation.

Key findings

  • Observed frequency of PMS diagnoses among individuals with autism across contributing sources ranged from 1% to ~2.5%.1%–2.5%
“The frequency of PMS diagnoses ranged from 1% to ~2.5%.”
What this piece can’t prove
  • Heterogeneity in assay sensitivity across contributing sources limits direct comparability of raw frequency estimates.
  • Descriptive range reflects diagnoses among autism-tested participants and requires additional adjustments/extrapolations to estimate general-population prevalence.
  • This analytic component is a supporting descriptive assessment embedded within a broader multisource modeling effort rather than an independent study design.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 29 candidate papers

Candidate

Puppets as mediators: Enhancing behavioral engagement in children with Autism Spectrum Disorder (ASD)

Research in Autism · 2026 · Crossref

Source (opens in a new tab)

And 23 more candidates considered.